← Back to headlines
Bayer's Xofigo/Xtandi Combination Shows Survival Benefit in Prostate Cancer
Bayer announced that its drug combination of Xofigo and Xtandi demonstrated an overall survival benefit in patients with prostate cancer, indicating a positive development in treatment options.
26 Feb, 19:36 — 26 Feb, 19:36
ℹOnly 1 source covers this story
